MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2023 International Congress

    Novelty Seeking: A Narrative Review

    K. Paulk, L. Neilson (Portland, USA)

    Objective: To explore novelty seeking (NS) as a construct, in both its adaptive and maladaptive roles, in order to provide insight into the cognitive and…
  • 2023 International Congress

    Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease

    V. Fung, J. Aldred, F. Bergquist, E. Danielsen, A. Jeong, J. Jia, A. Spiegel, S. Talapala, C. Carroll (Westmead, Australia)

    Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study. Background: LDP/CDP…
  • 2023 International Congress

    REM sleep behavior disorder in Parkinson´s Disease: a risk factor for Impulse Control Disorders.

    M. Vales Montero, A. Contreras Chicote, B. Delacasa Fages, J. Pérez Sánchez, E. Luque Buzo, M. González Sánchez, F. Grandas (Madrid, Spain)

    Objective: We aimed to analyze de association between REM sleep behavior disorder (RBD) and impulse control disorders (ICD) in Parkinson´s disease (PD) patients and in…
  • 2023 International Congress

    The efficacy of dopamine agonists or monoamine oxidase type B inhibitors as monotherapy in patients with early Parkinson disease: A network meta-analysis

    CSC. Chuang (Changhua, Taiwan)

    Objective: This study aimed to investigate the effectiveness of dopamine agonists or monoamine oxidase type B inhibitors (MAOB-I) as monotherapy in patients with early Parkinson's…
  • 2023 International Congress

    Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists in Parkinson’s disease uncontrolled by levodopa: final results of the PD MED LATER randomized clinical trial

    C. Clarke, C. Rick, S. Patel, R. Wooley, N. Rowland, J. Futterer, R. Ottridge, C. Jenkinson, R. Gray (Birmingham, United Kingdom)

    Objective: PD MED LATER is a large, pragmatic trial aiming to determine which class of drug when added to levodopa provides the most effective control…
  • 2023 International Congress

    Identification of xylopropamine as a potential dopamine D2 receptor agonist through computational drug discovery pipeline

    B. Ugbedeojo, P. Adoyi, A. Abah, O. Onimisi, S. Musa, A. Omoniyi (Zaria, Nigeria)

    Objective: This study aims to identify novel dopamine D2 receptor agonists through the computational drug discovery pipeline. Background: Parkinson's disease (PD) is a neurodegenerative disorder…
  • 2023 International Congress

    Impulse control disorder related to dopaminergic therapy in progressive supranuclear palsy

    T. Thammongkolchai, P. Termsarasab (Bangkok, Thailand)

    Objective: To report a patient with progressive supranuclear palsy (PSP) in whom an impulse control disorder (ICD) was triggered by a dopaminergic therapy. Background: ICDs…
  • 2022 International Congress

    Aromatic L-amino acid decarboxylase deficiency: A rare disease case report and literature review

    P. Bacus, R. Sauer, T. Kini, Z. Guduru, K. Jones (Lexington, USA)

    Objective: We review the presentation of a 3-month-old patient who came to our institution with symptoms of dystonia, oculogyric crises, hypotonia, developmental delay, and dysphagia,…
  • 2022 International Congress

    Experience with apomorphine infusion cartridge in France – evaluation of patient and healthcare team benefits

    M. Vérin, M. Demais (Rennes, France)

    Objective: To evaluate ‘real-world’ benefits for patients with Parkinson’s disease (PD) and impact on healthcare team practice of the introduction of apomorphine infusion (APO) cartridge…
  • 2022 International Congress

    USE OF NIGHT TIME CONTINUOUS SUBCUTANEOUS INFUSION OF APOMORPHINE (NCSAI) IN ADVANCED PARKINSON’S DISEASE: A SERIES OF 37 CASES.

    AK. Vargas Mendoza, B. López López, M. Díaz Castela, J. Molina Gil, P. Zunzunegui Arroyo, A. Criado Antón, ME. Suárez Sanmartín, C. García Fernández (Oviedo, Spain)

    Objective: The aim of this study is to evaluate the feasibility, efficacy and safety of NCSAI administration in patients with Advanced Parkinson disease (APD). Background:…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley